Core Viewpoint - The article highlights the successful IPO of Hangzhou Deshi Biotechnology Co., Ltd., which is one of the few companies focused on medical imaging AI to enter the capital market, raising approximately 800 million HKD through the issuance of 7.9992 million H-shares at 99 HKD per share [2][14]. Group 1: Company Overview - Deshi Biotechnology has established itself as a key player in the medical imaging AI sector, focusing on a specific application rather than a general model, with its core technology being the iMedImage® medical imaging base model [3][4]. - The company has developed a comprehensive business structure that includes medical imaging software, medical devices, reagents, consumables, and technology licensing, with applications in over 400 medical institutions [4]. Group 2: Product and Technology - The company's flagship product, AI AutoVision® chromosome karyotype auxiliary diagnostic system, has achieved a karyotype analysis accuracy of 99.86% and reduced reporting time from approximately 30 days to 4-7 days, addressing long-standing clinical issues related to manual operations [8]. - The sensitivity and specificity for detecting abnormal numbers and structural abnormalities are reported at 100.00% and 94.05% respectively, showcasing the effectiveness of the technology [9]. Group 3: Market Position and Growth - The IPO reflects a growing market interest in the medical imaging AI sector, with Deshi's revenue showing significant growth, reaching approximately 112 million CNY in the first three quarters of 2025, a year-on-year increase of about 470%, and a gross margin of 75.9% [14][15]. - The company is transitioning from a single product provider to a foundational capability supplier, with an evolving business model that includes technology licensing and platform delivery, indicating a shift in revenue structure [17][19]. Group 4: Industry Implications - The article suggests that the listing of companies like Deshi provides a reference path for the medical AI industry, emphasizing the importance of moving from technical capabilities to product implementation and scaling commercial operations [20].